It’s time for Dynavax to refocus.

For years, Dynavax’s Board has fruitlessly pursued a high-risk strategy to acquire, develop and commercialize a vaccine asset – diverting attention away from the Company’s priority of growing the market share of its lead asset, Heplisav. 

Meanwhile, excess cash has piled up to nearly half the Company’s market cap, raising concerns it may fund a value-destroying deal. 

Deep Track believes fresh, investor-aligned voices are needed on the Board to ensure capital decisions prioritize shareholder interests and maximize long-term value.

/ MEET OUR NOMINEES /

Deep Track Capital has nominated four director candidates who we believe will restore investor confidence in Dynavax.

Meet Our nominees

/ KEY ISSUES FACING DYNAVAX /

High-Risk Diversification StrategyHigh-Risk Diversification Strategy

High-Risk Diversification Strategy

The Board has been focused on acquiring a pre-commercial vaccine asset and developing it, but Dynavax has no obvious edge in vaccine development or commercialization – each of which is an extremely complex undertaking.

Inefficient Allocation of Excess CapitalInefficient Allocation of Excess Capital

Inefficient Allocation of Excess Capital

Instead of pursuing high return initiatives to grow Heplisav or returning excess capital to maximize value for shareholders, the Board continues to sit on excess cash which has grown to half of Dynavax's market cap.

Persistent Underperformance Despite Growing SalesPersistent Underperformance Despite Growing Sales

Persistent Underperformance Despite Growing Sales

Even though Heplisav sales grew more than fourfold from 2021 to 2024, DVAX shares have returned -43% since Scott Myers became Chariman in Oct. 2021, reflecting shareholders' concerns with the Company's capital allocation strategy.

Reduced Focus on the Heplisav OpportunityReduced Focus on the Heplisav Opportunity

Reduced Focus on the Heplisav Opportunity

The Board's pressure on management to identify external assets is diverting focus away from Dynavax's best opportunity to create shareholder value: growing Heplisav's market share.

Objective, investor-aligned perspectives are needed in the boardroom to independently evaluate the allocation of capital and help set a path to maximize long-term value for all shareholders.

Learn How TO Vote

/ WE WANT TO HEAR FROM YOU /

For Investors

Innisfree M&A Incorporated
Scott Winter / Gabrielle Wolf
+1 212-750-5833

For Media Inquiries

Longacre Square Partners
deeptrack@longacresquare.com

Subscribe for Updates

Enter your name and email address below to receive important updates

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.